David Beran1, Margaret Ewen2, Kasia Lipska3, Irl B Hirsch4, John S Yudkin5. 1. Division of Tropical and Humanitarian Medicine, University of Geneva and Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 6, 1211, Geneva, Switzerland. david.beran@unige.ch. 2. Health Action International, Amsterdam, The Netherlands. 3. Section of Endocrinology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. 4. University of Washington School of Medicine, Seattle, WA, USA. 5. Institute of Cardiovascular Science, Division of Medicine, University College London, London, UK.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to highlight the key issues with regard to the value, affordability, and availability of diabetes treatments. RECENT FINDINGS: Many of the medicines needed to manage diabetes are available as generics and, if purchased appropriately, can be made affordable to many individuals and systems. With new treatments for diabetes, additional costs to individuals and systems need to be assessed in terms of added clinical benefit and financial impact. As healthcare finances are limited, increased spending on diabetes medicines means fewer resources for other areas of diabetes care or for the population as a whole. This increased expenditure is driven by rising prevalence as well as the cost of newer treatments. With an increasing burden of disease and changing patterns of medicines in the market, we stress the need to focus attention on ensuring access for individuals to essential medicines. Universal health care offers unique opportunity to address the issue of access to medicines and the wider issues surrounding access to diabetes care, but this will require concerted action bringing together governments, civil society and the private sector.
PURPOSE OF REVIEW: The purpose of this review is to highlight the key issues with regard to the value, affordability, and availability of diabetes treatments. RECENT FINDINGS: Many of the medicines needed to manage diabetes are available as generics and, if purchased appropriately, can be made affordable to many individuals and systems. With new treatments for diabetes, additional costs to individuals and systems need to be assessed in terms of added clinical benefit and financial impact. As healthcare finances are limited, increased spending on diabetes medicines means fewer resources for other areas of diabetes care or for the population as a whole. This increased expenditure is driven by rising prevalence as well as the cost of newer treatments. With an increasing burden of disease and changing patterns of medicines in the market, we stress the need to focus attention on ensuring access for individuals to essential medicines. Universal health care offers unique opportunity to address the issue of access to medicines and the wider issues surrounding access to diabetes care, but this will require concerted action bringing together governments, civil society and the private sector.
Entities:
Keywords:
Diabetes; Health care costs; Health expenditure; Hypoglycemic agents; Insulin
Authors: A Siebenhofer; J Plank; A Berghold; K Jeitler; K Horvath; M Narath; R Gfrerer; T R Pieber Journal: Cochrane Database Syst Rev Date: 2006-04-19
Authors: Darrell J Gaskin; Roland J Thorpe; Emma E McGinty; Kelly Bower; Charles Rohde; J Hunter Young; Thomas A LaVeist; Lisa Dubay Journal: Am J Public Health Date: 2013-11-14 Impact factor: 9.308
Authors: Ahmadou M Jingi; Jean Jacques N Noubiap; Arnold Ewane Onana; Jobert Richie N Nansseu; Binhuan Wang; Samuel Kingue; André Pascal Kengne Journal: PLoS One Date: 2014-11-04 Impact factor: 3.240
Authors: Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse Journal: N Engl J Med Date: 2016-06-13 Impact factor: 176.079
Authors: Jean Paul Mukundiyukuri; Jean Jacques Irakiza; Naome Nyirahabimana; Loise Ng'ang'a; Paul H Park; Gedeon Ngoga; Ziad El-Khatib; Louis Nditunze; Etienne Dusengeyezu; Christian Rusangwa; Tharcisse Mpunga; Joel Mubiligi; Bethany Hedt-Gauthier Journal: Ann Glob Health Date: 2020-09-25 Impact factor: 2.462
Authors: Ileana Mardare; Stephen M Campbell; Johanna C Meyer; Israel Abebrese Sefah; Amos Massele; Brian Godman Journal: Front Pharmacol Date: 2022-01-14 Impact factor: 5.810
Authors: Brian Godman; Magdalene Wladysiuk; Stuart McTaggart; Amanj Kurdi; Eleonora Allocati; Mihajlo Jakovljevic; Francis Kalemeera; Iris Hoxha; Anna Nachtnebel; Robert Sauermann; Manfred Hinteregger; Vanda Marković-Peković; Biljana Tubic; Guenka Petrova; Konstantin Tachkov; Juraj Slabý; Radka Nejezchlebova; Iva Selke Krulichová; Ott Laius; Gisbert Selke; Irene Langner; András Harsanyi; András Inotai; Arianit Jakupi; Svens Henkuzens; Kristina Garuolienė; Jolanta Gulbinovič; Patricia Vella Bonanno; Jakub Rutkowski; Skule Ingeberg; Øyvind Melien; Ileana Mardare; Jurij Fürst; Sean MacBride-Stewart; Carol Holmes; Caridad Pontes; Corinne Zara; Marta Turu Pedrola; Mikael Hoffmann; Vasileios Kourafalos; Alice Pisana; Rita Banzi; Stephen Campbell; Bjorn Wettermark Journal: Biomed Res Int Date: 2021-10-11 Impact factor: 3.411